Factual Summary
Iovance Biotherapeutics is a company with the tumor-infiltrating lymphocyte (TIL)-based cell therapy Amtagvi (lifileucel), which received US FDA approval in 2024, followed by regulatory approvals in Canada in August 2025 and Australia in June 2026. Q1 2026 revenue was USD 71 million, up approximately 45% year-over-year, and the company issued full-year 2026 revenue guidance of USD 350-370 million (announced 2026-05-07). The 2026-07-28 closing price was USD 4.70, down -4.08% from the previous close, and that day's volume of 13.44 million shares was below the recent 20-trading-day average of 16.46 million shares.
Price-Change Context Note
Over the prior two weeks, the stock rose +19.8% on 2026-07-15 and set a 52-week high of USD 5.64 on 07-23; the 07-28 decline is observed, within the scope of confirmed available sources, as a pullback phase that occurred without any company-specific disclosure event. Short interest as a percentage of float has declined for a third consecutive month, from 32.69% as of the 2026-04-15 settlement date to approximately 24-26% as of the 2026-07-15 settlement date.
Business Overview & Pipeline
Iovance is the first company to commercialize a one-time, patient-specific T-cell therapy targeting solid tumors. Its lead product, Amtagvi (lifileucel), is indicated for adult patients with advanced melanoma previously treated with PD-1-blocking antibody therapy, with Proleukin (an IL-2 agent) used in combination as part of the treatment protocol. Manufacturing has transitioned fully in-house to the Iovance Cell Therapy Center, with the contract manufacturer ending production in Q1 2026 (2025 10-K).
Regulatory Approval Status
| Country | Status |
|---|---|
| United States | FDA approval in 2024 |
| Canada | Approved August 2025 |
| Australia | Conditional approval June 2026 |
| UK & Europe (EMA) | Under review/resubmission in progress, timing per company guidance |
| Switzerland | Possible approval in H1 2027 mentioned (guidance) |
Pipeline
- TILVANCE-301: a global Phase 3 confirmatory trial evaluating Amtagvi plus pembrolizumab as first-line treatment for advanced melanoma
- Non-small cell lung cancer: lifileucel granted Fast Track designation by the FDA
- Sarcoma: registrational program underway; specific clinical stage not available
- Endometrial cancer: early Phase 2 data — confirmed objective response rate of 40% in the first 5 patients; sample size is very small, warranting caution in interpretation
5-Year Financial Trend
| Fiscal Year | Revenue (USD millions) | Net Loss (USD millions) |
|---|---|---|
| 2023 | 1.2 | 444.0 |
| 2024 | 164.1 | 372.2 |
| 2025 | 263.5 | 391.0 |
| 2026 Q1 | 71.0 | Not available (quarterly figure not disclosed separately) |
Gross margin was approximately 41% in Q1 2026 (reflecting one-time costs), indicating a stable, high-margin structure has not yet been established. Accumulated deficit stood at approximately USD 2.9 billion as of 2026-03-31 (secondary source, needs cross-checking against the original 10-Q). Cash was approximately USD 319 million, and the company stated this would fund operations through 2028 (guidance), though some commentary presents conflicting statements, so this research does not make a definitive determination.
Valuation (Factual Multiples)
As of year-end 2025, P/S is calculated at approximately 4.27x; the discrepancy between companiesmarketcap.com (2.67x-4.27x) and a Yahoo Finance-cited article (8.6x) stems from differing revenue bases used (TTM actuals vs. a specific quarter annualized) — this could not be confirmed against original sources. EV/EBITDA and P/B are not available.
Competitive Landscape
| Company | Competition Type | Notes |
|---|---|---|
| Bristol Myers Squibb | Indirect (standard therapy) | Holds standard melanoma treatments including Opdivo and Yervoy |
| Obsidian Therapeutics | Direct (TIL/cell therapy) | Developing OBX-115 |
| Adaptimmune | Direct (TCR-based cell therapy) | Cited as a competitor (RocketReach) |
| Celyad Oncology | Direct (cell therapy) | Cited as a competitor |
| Vertex Pharmaceuticals | Potential substitute (allogeneic) | Developing off-the-shelf approaches including zimislecel |
Amtagvi is the only approved TIL cell therapy in the United States and Australia (labiotech.eu, as of 2025). Its autologous (patient-specific) manufacturing process takes approximately 34 days, which is cited as a structural scalability disadvantage relative to competing allogeneic technologies.
Supply-Demand (Institutional Ownership, Short Interest, Insiders)
13F institutional ownership is tallied at 292 institutions holding a combined approximately 295 million shares (secform4.com), though the ownership percentage figures range widely from 19.87% to 63.50% depending on the source, conflicting significantly, so this is not presented as a confirmed figure. A directional trend of increased holdings by major institutions including BlackRock and Vanguard is commonly observed across multiple sources, though exact share counts diverge between sources. Recently confirmed executive Form 4 filings mostly reflect acquisitions from RSU vesting and share dispositions for tax withholding purposes; no cases of discretionary large-scale open-market purchases or sales were identified.
Governance & Disclosures
Frederick G. Vogt (General Counsel and Director) has held the Interim Chief Executive Officer title continuously since June 2021, through the 2026-04-28 proxy statement. The CFO position changed twice during 2025, from Jean-Marc Bellemin to Matthew W. Rosinack (interim) to Corleen Roche, who formally assumed the role on 2025-08-06. The Board was re-elected with 6 members at the 2026-06-10 Annual Meeting (down from 7 previously), and authorized shares were increased from 500 million to 650 million (254,976,692 votes for vs. 71,438,492 against).
Macro Environment
| Factor | Current Value (as of) | Impact |
|---|---|---|
| Federal Reserve Funds Rate | 3.50-3.75% (held at 2026-06-17 decision) | Negative |
| US 10-Year Treasury Yield | 4.64-4.69% (late July 2026) | Negative |
| Biotech Sector Fund Flows (XBI) | +17.27% 1-month, +24.9% YTD (late July 2026) | Positive |
| Biotech Funding Market | Recovered to approx. USD 1.4 billion in new offerings in February 2026 (vs. 2025) | Positive |
| US Section 232 Pharmaceutical Tariffs | Phased implementation on 2026-07-31 and 09-29, applicability uncertain | Uncertain |
| US Consumer Confidence Index | 90.8 (July 2026, third consecutive monthly decline) | Weak negative |
As an early-commercial, pre-profit cell therapy company, Iovance's valuation and funding conditions are directly affected by long-term interest rate levels and broader biotech sector fund flows. Its cash position (approximately USD 319 million, which the company guides will fund operations through 2028) is observed as a factor cushioning near-term funding pressure.
Recent Disclosure & News Timeline
| Date | Description |
|---|---|
| 2026-02-24 | Q4 and full-year 2025 earnings release (full-year revenue approx. USD 264 million) |
| 2026-03-24 | Court approval of stipulated stay of derivative litigation proceedings related to securities class action |
| 2026-05-07 | Q1 2026 earnings release (revenue USD 71 million, net loss USD 79.0 million) |
| 2026-06-03 | Australia's TGA grants conditional approval for Amtagvi (third approving country) |
| 2026-06-10 | Annual Meeting (6 directors re-elected, authorized share increase, etc.) |
| 2026-06-23 | Registration disclosure for ATM equity offering program of up to USD 89.65 million |
| 2026-07-15 | Stock price +19.8% (no specific direct cause identified in available sources) |
| 2026-07-16 | Disclosure of approval of 139,930 inducement stock options granted to new non-executive employees |
| 2026-07-23 | 52-week high of USD 5.64 recorded |
| 2026-07-28 | Closing price USD 4.70 (-4.08%), no direct trigger identified |
Risk Factors
Financial & Funding
- Reports of approximately 62% growth in shares outstanding over the past year (secondary source, not yet cross-checked against original filings), and an active USD 350 million ATM program — potential for further dilution
- Conflicting statements on cash runway: company guidance (funded through 2028) vs. some commentary (less than one year of runway remaining) — not determined conclusively in this research
- Approximately 19% workforce reduction during 2026 (reported as aimed at extending cash runway)
Business Execution
- Achieving the midpoint of the 2026 full-year revenue guidance (USD 350-370 million) would require quarterly revenue in the second half to expand substantially versus Q1 2026 (USD 71 million)
- Q1 2026 gross margin of approximately 41%, indicating a stable high-margin structure has not yet been established
- Complexity of personalized cell therapy manufacturing — potential for supply disruption in the event of process issues (general industry consideration; no specific incident history identified)
- Uncertainty around the adequacy of insurance reimbursement for a high-cost therapy priced at approximately USD 515,000 per patient
Clinical & Regulatory
- Uncertainty tied to results of ongoing confirmatory trials including TILVANCE-301
- Endometrial cancer Phase 2 early data is based on only 5 patients (40% confirmed objective response rate) — sample size is very small, warranting caution in statistical interpretation
- Resubmission of the European (EMA) marketing authorization application is underway during 2026 — the reason for the initial application's rejection is not available
Competition
- Scalability limitations of the autologous manufacturing approach — potential structural disadvantage versus allogeneic competing technologies
- Competitive pressure from next-generation cell therapy pipelines such as Obsidian Therapeutics
Theme Relevance
Fact Highlights
This is not investment advice. FomoLog provides factual summaries and post-hoc price-change context only. Investment decisions and their outcomes are solely the responsibility of the investor.
Generated by FomoLog Agent · Data sources: KRX (Korea Exchange) · NASDAQ · DART · SEC EDGAR